Compare US Global Jets ETF (JETS) vs Johnson & Johnson (JNJ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
US Global Jets ETF vs Johnson & Johnson — how do they compare? US Global Jets ETF trades at $27.46 (market cap $878.48M), while Johnson & Johnson trades at $261.48 (market cap $618.09B). The key difference: Johnson & Johnson is far larger — about 703.6× US Global Jets ETF's market cap, and Johnson & Johnson pays a 2.09% dividend while US Global Jets ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold US Global Jets ETF for 26 Days and Johnson & Johnson for 129 Days on average.
| JETS | JNJ | |
|---|---|---|
Market Cap | $878.48M | $618.09B |
Volume | 4,465,925 | 6,050,983 |
Sector | Sector/Thematic | Health |
52-Week High | $33.53 | $278.43 |
52-Week Low | $23.64 | $186.00 |
Typical Hold Time | 26 Days | 129 Days |
Enterprise Value | — | $646.37B |
Dividend Yield | — | 2.09% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JETS ETF trades at $27.29, down 1.37% amid bearish technical signals with 17 sell indicators versus 4 buy signals. The airline-focused ETF faces headwinds from rising fuel costs and geopolitical tensions, while technical analysis shows strong resistance at $28 and support at $27. Recent news highlights underperformance compared to defense-focused aerospace ETFs and pressure from Middle East conflicts driving up airline operating expenses.
The outlook remains challenging with fuel cost volatility and competitive pressure from alternative aerospace investments. While travel demand provides some support, the ETF's concentration on airline operators exposes investors to cyclical industry risks and margin compression from elevated fuel expenses. Near-term performance depends on fuel price stabilization and geopolitical developments.
Johnson & Johnson (JNJ) trades at $261.44, up 1.16% with a bearish technical signal despite recent earnings beats. The company maintains strong fundamentals with $94.19B revenue, 21.48% net margin, and consistent dividend payments. Recent news highlights growth in the Innovative Medicine segment and positive analyst coverage with a $286.53 consensus target.
JNJ offers stable growth potential with diversified healthcare operations and robust profitability. Key risks include patent expirations, competitive pressures, and debt levels. Analyst consensus leans bullish with 52.5% buy ratings, though technical indicators suggest near-term caution. The stock presents a balanced opportunity for long-term investors seeking healthcare exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About US Global Jets ETF
JETS provides targeted exposure to the global airline industry, including commercial airlines, aircraft manufacturers, and airport operators. It focuses on major U.S. and international carriers like Delta, United, and American Airlines.
Read more on JETS →About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →
